Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells

Neurobiology of Disease
Seung-Yong YoonDong-Hou Kim

Abstract

Increasing evidence supports an association between Alzheimer's disease (AD) and diabetes. Rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, which is an anti-diabetic agent against type 2 diabetes, is currently in Phase III clinical trials in AD patients because rosiglitazone reduces β-amyloid (Aβ) pathology and inflammation. However, few studies have investigated whether rosiglitazone affects tau phosphorylation, another critical pathological feature of AD. Thus, we investigated it using OLETF type 2 diabetic rats and streptozotocin-injected type 1 diabetic mice. Interestingly, rosiglitazone reduced tau phosphorylation only in the hippocampus of OLETF type 2 diabetes rats, and not in that of STZ-injected type 1 diabetes mice. The activity of JNK was reduced in the hippocampus of rosiglitazone-treated OLETF rats, correlating with a reduction in tau phosphorylation, however, which was not correlated with GSK3β activity. In human tau-transfected SH-SY5Y neuronal cell line, reduction of tau phosphorylation was also associated with reduction of JNK activity, not of GSK3β activity. Hence, rosiglitazone could be used in reducing tau phosphorylation through JNK inactivation for therapeutic effects in type ...Continue Reading

References

Jul 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·I Grundke-IqbalL I Binder
Dec 1, 1984·The American Journal of Medicine·L C PerlmuterD M Nathan
Jan 30, 2004·Diabetes·Juliette JansonPeter C Butler
Apr 4, 2007·Neurobiology of Aging·Fernanda G De FeliceWilliam L Klein
Apr 26, 2007·Diabetes·Zhen-guo LiAnders A F Sima
Dec 14, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Emmanuel PlanelAkihiko Takashima
Apr 26, 2008·Endocrine Reviews·Christopher T Kodl, Elizabeth R Seaquist
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Gary LandrethMichael Heneka
Oct 22, 2008·Oncogene·D N Dhanasekaran, E P Reddy
Jun 16, 2009·Neuropharmacology·Changiz TaghibiglouYu Tian Wang
Mar 26, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Luis EscribanoDiana Frechilla

❮ Previous
Next ❯

Citations

Sep 29, 2011·PloS One·Meghana TareAmit Singh
Mar 20, 2012·Pharmacology, Biochemistry, and Behavior·Jiejie LiZhiyi Zuo
Oct 4, 2012·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Nobuya OkamiPak H Chan
Nov 21, 2015·PPAR Research·María José Pérez, Rodrigo A Quintanilla
Nov 13, 2015·Substance Abuse : Research and Treatment·Ingunn Olea Lund, Anne Bukten
Jan 25, 2019·British Journal of Pharmacology·Judit M Perez Ortiz, Russell H Swerdlow
Sep 11, 2014·The Journal of Biological Chemistry·Maysa Ahmed MobasherÁngela M Valverde
Nov 17, 2014·Metabolic Brain Disease·Zhiyou CaiLiang-Jun Yan
Oct 10, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Xiaodan QuXueshi Huang
Jul 11, 2020·European Journal of Pharmacology·Moumita NathYashmin Choudhury
Oct 13, 2019·Current Medicinal Chemistry·Agnieszka JankowskaGrażyna Chłoń-Rzepa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Alzheimer's Disease: Animal Models

Alzheimer's disease is a neurodegenerative disease which can be studied using various experimental systems. This feed focuses on animal models used for Alzheimer's disease research.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.